Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells
Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis...
Gespeichert in:
Veröffentlicht in: | Autophagy 2018-12, Vol.14 (12), p.2083-2103 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2103 |
---|---|
container_issue | 12 |
container_start_page | 2083 |
container_title | Autophagy |
container_volume | 14 |
creator | Zhang, Zili Yao, Zhen Wang, Ling Ding, Hai Shao, Jiangjuan Chen, Anping Zhang, Feng Zheng, Shizhong |
description | Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis.
Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HC |
doi_str_mv | 10.1080/15548627.2018.1503146 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_30081711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2084923754</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</originalsourceid><addsrcrecordid>eNp9kc1uGyEUhVGVqknTPkIrltmMA8PPwCaKFaVJJauVorZbxMyATTWGCTCJvOybB8eOlWy6uoj7nXNAB4AvGM0wEugcM0YFr5tZjbCYYYYIpvwdONneV4ITdnQ4180x-JjSX4QIF7L-AI4JQgI3GJ-Af_MuuwedXfAwWGhNjC47H8aVXm6gSzCa-8lF00MbIswrA-9-zKvW-d75JRxjyMZ5eL2Y_1ng89vpDuZQJMtp0Nk8u4Uxh1R8CrUyYwnqYMpmeN53ZaZP4L3VQzKf9_MU_P52_evqtlr8vPl-NV9UHSM0V5xILgxrJSGcUdkQ0ddGC6xbK4WVmFphLbG9KDQmglPJiCE9qjlpedMLcgoudr7j1K5N3xmfox7UGN1ax40K2qm3G-9WahkeFJeCNpwVg7O9QQz3k0lZrV3afkF7E6akaiSorEnDaEHZDu1iSCkae4jBSG3rUy_1qW19al9f0X19_caD6qWvAlzuAOdLH2v9GOLQq6w3Q4g2at-5pMj_M54A6NWrgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2084923754</pqid></control><display><type>article</type><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</creator><creatorcontrib>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</creatorcontrib><description>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis.
Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</description><identifier>ISSN: 1554-8627</identifier><identifier>EISSN: 1554-8635</identifier><identifier>DOI: 10.1080/15548627.2018.1503146</identifier><identifier>PMID: 30081711</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autophagy ; Autophagy - drug effects ; Autophagy - genetics ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - pathology ; Cell Death - drug effects ; Cell Death - physiology ; Cells, Cultured ; Chemical and Drug Induced Liver Injury - genetics ; Chemical and Drug Induced Liver Injury - metabolism ; Chemical and Drug Induced Liver Injury - pathology ; ELAV-Like Protein 1 - genetics ; ELAV-Like Protein 1 - physiology ; ELAVL1 ; Female ; ferritinophagy ; ferroptosis ; hepatic stellate cell ; Hepatic Stellate Cells - drug effects ; Hepatic Stellate Cells - metabolism ; Hepatic Stellate Cells - pathology ; Humans ; Iron - pharmacology ; Lipid Peroxidation - drug effects ; Lipid Peroxidation - physiology ; Liver Cirrhosis - chemically induced ; Liver Cirrhosis - genetics ; Liver Cirrhosis - metabolism ; Liver Cirrhosis - pathology ; liver fibrosis ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Research Paper - Basic Science ; Retrospective Studies ; Sorafenib - administration & dosage ; Sorafenib - adverse effects ; Sorafenib - pharmacology ; therapeutic target</subject><ispartof>Autophagy, 2018-12, Vol.14 (12), p.2083-2103</ispartof><rights>2018 Informa UK Limited, trading as Taylor & Francis Group 2018</rights><rights>2018 Informa UK Limited, trading as Taylor & Francis Group 2018 Informa UK Limited, trading as Taylor & Francis Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</citedby><cites>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984765/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984765/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30081711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Zili</creatorcontrib><creatorcontrib>Yao, Zhen</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Ding, Hai</creatorcontrib><creatorcontrib>Shao, Jiangjuan</creatorcontrib><creatorcontrib>Chen, Anping</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><creatorcontrib>Zheng, Shizhong</creatorcontrib><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><title>Autophagy</title><addtitle>Autophagy</addtitle><description>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis.
Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autophagy</subject><subject>Autophagy - drug effects</subject><subject>Autophagy - genetics</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Death - drug effects</subject><subject>Cell Death - physiology</subject><subject>Cells, Cultured</subject><subject>Chemical and Drug Induced Liver Injury - genetics</subject><subject>Chemical and Drug Induced Liver Injury - metabolism</subject><subject>Chemical and Drug Induced Liver Injury - pathology</subject><subject>ELAV-Like Protein 1 - genetics</subject><subject>ELAV-Like Protein 1 - physiology</subject><subject>ELAVL1</subject><subject>Female</subject><subject>ferritinophagy</subject><subject>ferroptosis</subject><subject>hepatic stellate cell</subject><subject>Hepatic Stellate Cells - drug effects</subject><subject>Hepatic Stellate Cells - metabolism</subject><subject>Hepatic Stellate Cells - pathology</subject><subject>Humans</subject><subject>Iron - pharmacology</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Lipid Peroxidation - physiology</subject><subject>Liver Cirrhosis - chemically induced</subject><subject>Liver Cirrhosis - genetics</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Cirrhosis - pathology</subject><subject>liver fibrosis</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Middle Aged</subject><subject>Research Paper - Basic Science</subject><subject>Retrospective Studies</subject><subject>Sorafenib - administration & dosage</subject><subject>Sorafenib - adverse effects</subject><subject>Sorafenib - pharmacology</subject><subject>therapeutic target</subject><issn>1554-8627</issn><issn>1554-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uGyEUhVGVqknTPkIrltmMA8PPwCaKFaVJJauVorZbxMyATTWGCTCJvOybB8eOlWy6uoj7nXNAB4AvGM0wEugcM0YFr5tZjbCYYYYIpvwdONneV4ITdnQ4180x-JjSX4QIF7L-AI4JQgI3GJ-Af_MuuwedXfAwWGhNjC47H8aVXm6gSzCa-8lF00MbIswrA-9-zKvW-d75JRxjyMZ5eL2Y_1ng89vpDuZQJMtp0Nk8u4Uxh1R8CrUyYwnqYMpmeN53ZaZP4L3VQzKf9_MU_P52_evqtlr8vPl-NV9UHSM0V5xILgxrJSGcUdkQ0ddGC6xbK4WVmFphLbG9KDQmglPJiCE9qjlpedMLcgoudr7j1K5N3xmfox7UGN1ax40K2qm3G-9WahkeFJeCNpwVg7O9QQz3k0lZrV3afkF7E6akaiSorEnDaEHZDu1iSCkae4jBSG3rUy_1qW19al9f0X19_caD6qWvAlzuAOdLH2v9GOLQq6w3Q4g2at-5pMj_M54A6NWrgw</recordid><startdate>20181202</startdate><enddate>20181202</enddate><creator>Zhang, Zili</creator><creator>Yao, Zhen</creator><creator>Wang, Ling</creator><creator>Ding, Hai</creator><creator>Shao, Jiangjuan</creator><creator>Chen, Anping</creator><creator>Zhang, Feng</creator><creator>Zheng, Shizhong</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181202</creationdate><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><author>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autophagy</topic><topic>Autophagy - drug effects</topic><topic>Autophagy - genetics</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Death - drug effects</topic><topic>Cell Death - physiology</topic><topic>Cells, Cultured</topic><topic>Chemical and Drug Induced Liver Injury - genetics</topic><topic>Chemical and Drug Induced Liver Injury - metabolism</topic><topic>Chemical and Drug Induced Liver Injury - pathology</topic><topic>ELAV-Like Protein 1 - genetics</topic><topic>ELAV-Like Protein 1 - physiology</topic><topic>ELAVL1</topic><topic>Female</topic><topic>ferritinophagy</topic><topic>ferroptosis</topic><topic>hepatic stellate cell</topic><topic>Hepatic Stellate Cells - drug effects</topic><topic>Hepatic Stellate Cells - metabolism</topic><topic>Hepatic Stellate Cells - pathology</topic><topic>Humans</topic><topic>Iron - pharmacology</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Lipid Peroxidation - physiology</topic><topic>Liver Cirrhosis - chemically induced</topic><topic>Liver Cirrhosis - genetics</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Cirrhosis - pathology</topic><topic>liver fibrosis</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Middle Aged</topic><topic>Research Paper - Basic Science</topic><topic>Retrospective Studies</topic><topic>Sorafenib - administration & dosage</topic><topic>Sorafenib - adverse effects</topic><topic>Sorafenib - pharmacology</topic><topic>therapeutic target</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zili</creatorcontrib><creatorcontrib>Yao, Zhen</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Ding, Hai</creatorcontrib><creatorcontrib>Shao, Jiangjuan</creatorcontrib><creatorcontrib>Chen, Anping</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><creatorcontrib>Zheng, Shizhong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autophagy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zili</au><au>Yao, Zhen</au><au>Wang, Ling</au><au>Ding, Hai</au><au>Shao, Jiangjuan</au><au>Chen, Anping</au><au>Zhang, Feng</au><au>Zheng, Shizhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</atitle><jtitle>Autophagy</jtitle><addtitle>Autophagy</addtitle><date>2018-12-02</date><risdate>2018</risdate><volume>14</volume><issue>12</issue><spage>2083</spage><epage>2103</epage><pages>2083-2103</pages><issn>1554-8627</issn><eissn>1554-8635</eissn><abstract>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis.
Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>30081711</pmid><doi>10.1080/15548627.2018.1503146</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1554-8627 |
ispartof | Autophagy, 2018-12, Vol.14 (12), p.2083-2103 |
issn | 1554-8627 1554-8635 |
language | eng |
recordid | cdi_pubmed_primary_30081711 |
source | Open Access: PubMed Central; MEDLINE; EZB Electronic Journals Library |
subjects | Adult Aged Aged, 80 and over Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autophagy Autophagy - drug effects Autophagy - genetics Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - pathology Cell Death - drug effects Cell Death - physiology Cells, Cultured Chemical and Drug Induced Liver Injury - genetics Chemical and Drug Induced Liver Injury - metabolism Chemical and Drug Induced Liver Injury - pathology ELAV-Like Protein 1 - genetics ELAV-Like Protein 1 - physiology ELAVL1 Female ferritinophagy ferroptosis hepatic stellate cell Hepatic Stellate Cells - drug effects Hepatic Stellate Cells - metabolism Hepatic Stellate Cells - pathology Humans Iron - pharmacology Lipid Peroxidation - drug effects Lipid Peroxidation - physiology Liver Cirrhosis - chemically induced Liver Cirrhosis - genetics Liver Cirrhosis - metabolism Liver Cirrhosis - pathology liver fibrosis Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - pathology Male Mice Mice, Inbred C57BL Middle Aged Research Paper - Basic Science Retrospective Studies Sorafenib - administration & dosage Sorafenib - adverse effects Sorafenib - pharmacology therapeutic target |
title | Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T11%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20ferritinophagy%20is%20required%20for%20the%20RNA-binding%20protein%20ELAVL1/HuR%20to%20regulate%20ferroptosis%20in%20hepatic%20stellate%20cells&rft.jtitle=Autophagy&rft.au=Zhang,%20Zili&rft.date=2018-12-02&rft.volume=14&rft.issue=12&rft.spage=2083&rft.epage=2103&rft.pages=2083-2103&rft.issn=1554-8627&rft.eissn=1554-8635&rft_id=info:doi/10.1080/15548627.2018.1503146&rft_dat=%3Cproquest_pubme%3E2084923754%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2084923754&rft_id=info:pmid/30081711&rfr_iscdi=true |